Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ROIV - Roivant Sciences Ltd.
Market Cap 9.06B P/E - EPS this Y 22.80% Ern Qtrly Grth -
Income -1.08B Forward P/E -10.83 EPS next Y 3.30% 50D Avg Chg 15.00%
Sales 78.58M PEG - EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 7.75 EPS next 5Y - 52W High Chg -2.00%
Recommedations 1.80 Quick Ratio 6.02 Shares Outstanding 779.30M 52W Low Chg 311.00%
Insider Own 34.48% ROA -27.95% Shares Float 255.09M Beta 1.28
Inst Own 58.52% ROE -77.38% Shares Shorted/Prior 21.19M/21.10M Price 11.81
Gross Margin - Profit Margin - Avg. Volume 4,793,029 Target Price 15.63
Oper. Margin -1,347.81% Earnings Date Nov 13 Volume 1,997,846 Change -1.01%
Healthcare | Biotechnology | United Kingdom
About Roivant Sciences Ltd.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd. News
09/09/23 The Brash Strategy That Made Vivek Ramaswamy a Fortune
08/17/23 Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
08/15/23 What You Need To Know About The Roivant Sciences Ltd. (NASDAQ:ROIV) Analyst Downgrade Today
08/14/23 Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
08/03/23 Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
08/02/23 Roivant Announces Redemption of Outstanding Warrants
07/27/23 Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
07/26/23 ‘Big Short’ Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge — Here Are 2 Stocks That Analysts Like
07/11/23 Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
06/28/23 UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
06/28/23 Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
06/26/23 Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
06/22/23 Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
06/21/23 Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
05/16/23 Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
04/04/23 Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
04/04/23 Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
03/28/23 Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
03/15/23 Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
03/14/23 Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
ROIV Chatroom

User Image Yankees4027 Posted - 6 hours ago

$ROIV how can anyone be bullish on this POFS! Utter trash!

User Image frontiere Posted - 7 hours ago

@Night_Owl_Biotech hi thanks for a genuine response. How about taking $ROIV (for Vtama) & $INCY (for Opzelura) as more relevant comps vs $ARQT ?

User Image arthura Posted - 2 days ago

$ROIV Closed green but still hope we lost some more F’n Pikers today…just sayin’! Have a good weekend all and hope we can weed some more out next week. LFG!!!

User Image jmashen Posted - 2 days ago

$ROIV Blocked.

User Image Jmac98 Posted - 3 days ago

$ROIV Where do we trade on +/- $IMVT data next week?

User Image Yankees4027 Posted - 3 days ago

$ROIV what’s todays excuse, the surge of illegals?

User Image StockAutomatePro Posted - 3 days ago

$ROIV The stock looks poised for a drop according to the chart. We alerted the SELL signal at $11.38 and we were able to close this one with profit at $10.22 🥳

User Image cctranscripts Posted - 3 days ago

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12558754 $ROIV

User Image cctranscripts Posted - 3 days ago

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12558762 $ROIV

User Image cctranscripts Posted - 3 days ago

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12558761 $ROIV

User Image MaxBloodGore Posted - 3 days ago

$ROIV I sold at 12.11, but this is starting to look real juicy again. On watch for tomorrow, I want sub 10s and will load heavy.

User Image AquisitionMagician Posted - 4 days ago

$ROIV so buy at $10 sell at $10.10 and repeat all day?

User Image Yankees4027 Posted - 4 days ago

$ROIV scam

User Image AquisitionMagician Posted - 4 days ago

$ROIV anyone get in around $10 this morning? I missed it. 😢

User Image Mtrinidad_76 Posted - 4 days ago

$ROIV getting ready to unload it all before its worthless again. It's just unbelievable.

User Image Thepatientone Posted - 4 days ago

$ROIV It will bounce back, resilience and the pipeline will deliver amazing news.

User Image GregK13 Posted - 4 days ago

$ROIV Unbelievable

User Image Krazedkujo Posted - 4 days ago

$ROIV Stochastics over sold, do we bounce of this support or with insider sales keep flushing towards the 200? On watch

User Image cctranscripts Posted - 4 days ago

Roivant Sciences Ltd. insider just disposed of 6,752 shares https://www.conferencecalltranscripts.org/summary/?id=12555475 $ROIV

User Image cctranscripts Posted - 4 days ago

Roivant Sciences Ltd. insider just disposed of 8,703 shares https://www.conferencecalltranscripts.org/summary/?id=12555474 $ROIV

User Image Jdvm Posted - 4 days ago

$ROIV I think t2 biosystems would be a perfect partner for us. What Do you guys think? They need cash.

User Image brs555 Posted - 4 days ago

$ROIV $COCO $IONQ Rolling over. A lot of failed new highs. Falling through the 50 day. Test the 200 day? Sell September apparently.. Know what you own.

User Image GregK13 Posted - 4 days ago

$ROIV apparently all growth stocks down

User Image AquisitionMagician Posted - 5 days ago

$ROIV what a bounce off 10.39. I feel like someone keeps taking 5 and 10 cent scalps. With recent insider sales and no news does feel like something is going to happen but who knows when and what the value will be. My thought is if you can pick up shares between $9.75 and $10.50 it should be ok. But agree with the cautious optimism.

User Image Yankees4027 Posted - 5 days ago

$ROIV this POFS just loves red

User Image PatBull6912 Posted - 5 days ago

$ROIV I suspect ROIV stock will recover some ground on Thu/Fri. But it's been acting very weird this last week - so be cautious... Like many here, I'm holding long though.

User Image GregK13 Posted - 5 days ago

$ROIV No where but up. Analysts aren’t wrong on this one

User Image AquisitionMagician Posted - 5 days ago

$ROIV Based on 9 Analyst’s ratings over last 3 months “strong buy” consensus.

User Image AquisitionMagician Posted - 5 days ago

$ROIV guess it will come down to how much someone is going to pay for the drug. Don’t think it’s an “if” scenario but a “when” and how much.

User Image GregK13 Posted - 5 days ago

$ROIV

Analyst Ratings
Cantor Fitzgerald Overweight Sep 18, 23
Cantor Fitzgerald Overweight Sep 5, 23
Cantor Fitzgerald Overweight Aug 31, 23
Cantor Fitzgerald Overweight Aug 22, 23
HC Wainwright & Co. Buy Aug 15, 23
Truist Securities Buy Jul 14, 23
HC Wainwright & Co. Buy Jun 29, 23
Truist Securities Buy Jun 23, 23
HC Wainwright & Co. Buy Jun 23, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Sell 12.19 106,430 1,297,382 611,813 09/12/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 08 Option 3.85 106,430 409,756 718,243 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Sell 12.18 99,350 1,210,083 197,950 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 08 Option 6.48 99,350 643,788 297,300 09/12/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Sell 12 1,724 20,688 197,950 09/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Sep 05 Option 6.48 1,724 11,172 199,674 09/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Sell 11.89 93,964 1,117,232 611,813 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Sep 04 Option 3.85 93,964 361,761 617,739 09/06/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Sell 11.89 59,811 711,153 627,918 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 14 Option 3.85 59,811 230,272 687,729 08/16/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Sell 11.93 44,629 532,424 627,918 08/07/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Aug 03 Option 3.85 44,629 171,822 672,547 08/07/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Sell 12 4,017 48,204 199,328 08/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Aug 01 Option 6.48 4,017 26,030 203,009 08/03/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Sell 11.9 195,166 2,322,475 627,918 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 31 Option 3.85 195,166 751,389 644,315 08/02/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Sell 10.92 125,534 1,370,831 627,918 07/27/23
Venker Eric Chief Operating Offi.. Chief Operating Officer Jul 25 Option 3.85 125,534 483,306 651,540 07/27/23
Venker Eric President & COO President & COO Jul 20 Sell 11.12 374,466 4,164,062 644,215 07/24/23
Venker Eric President & COO President & COO Jul 20 Option 3.85 374,466 1,441,694 677,296 07/24/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Sell 12 635 7,620 82,128 07/18/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jul 14 Option 6.48 635 4,115 82,228 07/18/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
VIKING GLOBAL PERFORMANCE LLC 10% Owner 10% Owner Jun 22 Sell 9.9 13,000,000 128,700,000 12,884,307 06/26/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Option 5.12 43,893 224,732 242,475 06/13/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Jun 09 Sell 9.93 43,893 435,857 198,582 06/13/23
Venker Eric President & COO President & COO Jun 07 Sell 9.88 299,585 2,959,900 660,097 06/09/23
Venker Eric President & COO President & COO Jun 07 Option 3.85 299,585 1,153,402 959,481 06/09/23
Venker Eric President & COO President & COO May 23 Sell 9.85 415 4,088 675,768 05/25/23
Venker Eric President & COO President & COO May 23 Option 3.85 415 1,598 676,183 05/25/23
Venker Eric President & COO President & COO May 09 Sell 9.23 238,724 2,203,423 675,768 05/11/23
Venker Eric President & COO President & COO May 09 Option 3.85 238,724 919,087 914,492 05/11/23
Venker Eric President & COO President & COO May 04 Sell 8.62 150,044 1,293,379 675,768 05/08/23
Venker Eric President & COO President & COO May 04 Option 3.85 150,044 577,669 736,974 05/08/23
Venker Eric President & COO President & COO May 01 Sell 8.43 288,989 2,436,177 675,768 05/03/23
Venker Eric President & COO President & COO May 01 Option 3.85 288,989 1,112,608 794,528 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Option 3.85 77,736 299,284 215,656 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer May 01 Sell 8.5 77,736 660,756 200,139 05/03/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Sell 8.55 230,788 1,973,237 200,139 04/28/23
Kumar Rakhi Chief Accounting Off.. Chief Accounting Officer Apr 26 Option 3.9 230,788 900,073 272,128 04/28/23
Venker Eric President & COO President & COO Apr 26 Sell 8.55 222,243 1,900,178 675,768 04/28/23
Venker Eric President & COO President & COO Apr 26 Option 3.85 222,243 855,636 751,591 04/28/23
SVF Investments (UK) Ltd 10% Owner 10% Owner Mar 20 Sell 8.00 12,000,000 96,000,000 83,031,667 03/22/23
Pulik Richard CFO CFO Mar 01 Sell 8.08 1,912 15,449 223,347 03/03/23
Venker Eric President & COO President & COO Jan 05 Sell 8.02 24,037 192,777 729,429 01/06/23
Venker Eric President & COO President & COO Dec 30 Sell 7.66 119,245 913,417 753,466 01/04/23
Venker Eric President & COO President & COO Dec 08 Sell 7.02 145,105 1,018,637 888,742 12/09/22
Venker Eric President & COO President & COO Dec 08 Sell 7.02 145,105 1,018,637 888,742 12/09/22
SVF Investments (UK) Ltd 10% Owner 10% Owner Nov 10 Sell 4.75 4,343,919 20,633,615 95,031,667 11/15/22
QVT Financial LP Director Director Nov 09 Sell 4.75 5,656,081 26,866,385 5,470,181 11/14/22